I
matinib mesylate revolutionized the management of chronic myelogenous leukemia and represents the new standard of care for this disease. 1 Most patients retain a residual disease and increasing numbers of resistant patients accumulate. The onset of ABL point mutations is the most frequent identified mechanism responsible for resistance. 2 Up to 30 different mutations have been described, mostly in advanced phase, 3 and confer different levels of clinical resistance. In this setting, trials with second generation tyrosine kinase inhibitors (TKIs) 4, 5 provide encouraging results, however neither in vitro nor clinical activity was demonstrated when a T315I was identified. 6, 7 In this multicentric retrospective study, we analysed 27 BCR-ABL T315I mutated CML patients exhibiting either clinical, cytological, cytogenetic resistance or molecular progression.
Design and Methods

BCR-ABL
T315I mutations have been identified in the 5 different laboratories and clinical data were retrospectively collected according to each centre ethical guidelines.
Resistance was defined according to the ELN guidelines 3 and if any hematological, cytogenetic or molecular progression (i.e. increasing BCR-ABL/ABL ratio ≥2 logs) of CML in a previously IM-responsive patient was observed.
The mutation was detected on blood samples analyzed according to the methods described by Branford et al. 8 by direct sequencing (on both strands) encompassing the entire ABL kinase and ATP-loop domains [residues 242-487].
Survival and time-to-progression curves were established from IM initiation to death or progression, according to Kaplan-Meier method. Progression was defined as any loss of previous response, and transition to a more advanced disease phase.
Calculations were performed using S-plus program (Insightful, Seattle, WA, USA). 3 with, no responses in 2 (7.5%), 14 (52%) CHR, 2 (7.5%) PCyR, 9 (33%) CCyR, 2 of whom 2 were in major molecular response. With a median follow-up of 21 months. Since IM initiation, and worryingly, all patients progressed after a median of 13 (0-49.6) months for all phases ( Figure 1A ), with 11 (41%) patients in CP and 16 (59%) in advanced phase [4 accelerated, 12 (7 myeloid + 5 lymphoid) BC] at progression. Time-to-progression 
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was significantly longer for patients in CP (18 months) versus advanced phases (12 months, p=0.04). Twelve/15 evaluable patients (80%) presented a clonal evolution at T315I identification (4 of which were already present at diagnosis) with no significant impact on survival (p=0.22). Likewise, the T315I mutation was discovered with additional mutations in 6 patients (1 Y253H, 2 M351T, 1 E255K and E255V, 1 L324Q, and 1 F311L), but these had no impact on overall survival (p= 0.91).
In this retrospective analysis, fourteen/18 (78%) evaluable patients were found challenged with higher doses of IM (600-800 mg/day), with one return to CP and one transient CCyR after IM combined with chemotherapy, and 12 failures. Six patients (1 CP, 5 BC) were treated with dasatinib, and no difference in survival was seen between dasatinib-treated and non-treated patients (p=0.15). None of the patients received nilotinib. Additionally, 3 patients underwent allogeneic stem cell transplantation with 2 remaining alive at 1 and 14 months follow-up. Finally, at latest follow-up, overall survival since IM initiation ( Figure 1B) , however longer for CP (42.5 Mo.) was not statistically different than that for AP+BC (17.5 Mo., p=0.08) patients.
The onset of BCR-ABL T315I mutations during the treatment of CML with TKIs remains challenging, because this mutation is the most frequently identified in IM-treated patients 6 , and none of the TKIs clinically available to date 4, 5, 6 retain any activity in vitro. More over, the continuation of these inhibitors might elicit the outgrowth of T315I clones as shown in the past. 9, 10, 11 In 5/6 patients receiving dasatinib, the BCR-ABL T315I mutation was assessed (through direct sequencing method) and absent before the introduction of this TKI, but present after a median of 4 months. The PCR-ASO was retrospectively performed in 2 patients (UPN#16 and 17) and demonstrated that the BCR-ABL T315I mutation was already present at low levels before dasatinib. Two/6 patients remained alive at latest follow-up, as dasatinib was immediately withdrawn when the T315I was identified. Thus, if a BCR-ABL T315I mutation is identified in a CML patient, TKI treatment withdrawal should be the first therapeutic intervention recommended.
Despite low number of patients and the limitations of such an analysis, we were able to show in this study that the onset of BCR-AB LT315I mutations occurs in a category of CML patients with poor initial prognostic features (poor Sokal scores, additional chromosomal abnormalities, poor response to IM), mostly in advanced phases. It is unknown whether the presence of a BCR-ABL T315I mutation is actually responsible for progression or if this mutation simply co-migrates with other general factors of progression such as clonal evolution or additional mutations. The first hypothesis is supported by in vitro studies 12 which demonstrate that a BCR-ABL mutation provides the mutated clone with a proliferative advantage over BCR-ABLWT cells and favors disease transformation potency. In our study, it is of note that 3/16 evaluable patients (UPN# 11, 17, 19) had neither chromosomal abnormalities other than the Ph1, nor additional mutation at T315I identification. In addition, previous studies 13, 14 have failed to detect c-kit and PDGF-R mutations in patients resistant to IM, suggesting that disease progression might be induced solely by BCR-ABL modifications. However, additional genetics abnormalities affecting other not-investigated/unknown BCR-ABL independent mechanisms of IM resistance/progression . The second hypothesis is supported by crystallographic analysis 16 showing that the lack of the critical hydrogen bond that disrupts IM binding during T315I residues exchanges is associated with the modification of multiple other protein-drug interactions that could participate to the deregulation of ABL tyrosine kinase activity. Others have shown 15 that various intracellular proteins, including STAT-5, might be altered in BCR-ABL T315I+ cells. In conclusion, despite the obvious limits of such a retrospective study, we show that the BCR-ABLT 315I mutation occurs probably in CML patients with poor initial prognostic features, and at high risk of disease progression. Subsequently, serial BCR-ABL mutation assessments throughout the course of the disease is recommended for IM-resistant patients for early detection of the BCR-ABL mutations.
Simple TKI withdrawal might-at least transiently-slow down disease progression and allow a sufficient timeframe for the seek of alternative therapeutic options such as the identification of a suitable donor for allogeneic stem cell transplantation, a suitable option to consider 17 or the use of aurora-kinase inhibitors (i. e. MK 0457) that might be active in this setting. 
